Levofloxacin: Indications, Dosing, Duration, and Contraindications
Levofloxacin is FDA-approved for adults at doses of 250 mg, 500 mg, or 750 mg once daily for 3-14 days depending on the infection type, with the 750 mg high-dose, 5-day regimen specifically approved for community-acquired pneumonia, acute bacterial sinusitis, complicated urinary tract infections, and acute pyelonephritis. 1
FDA-Approved Indications in Adults
Levofloxacin is approved for the following infections 1:
- Community-acquired pneumonia (CAP): 750 mg daily for 5 days OR 500 mg daily for 7-14 days
- Nosocomial (hospital-acquired) pneumonia: 750 mg daily for 7-14 days
- Acute bacterial sinusitis: 750 mg daily for 5 days OR 500 mg daily for 10-14 days
- Acute bacterial exacerbation of chronic bronchitis: 500 mg daily for 7 days
- Complicated urinary tract infections and acute pyelonephritis: 750 mg daily for 5 days OR 250 mg daily for 10 days
- Uncomplicated urinary tract infections: 250 mg daily for 3 days
- Complicated skin and skin structure infections: 750 mg daily for 7-14 days
- Uncomplicated skin infections: 500 mg daily for 7-10 days
- Chronic bacterial prostatitis: 500 mg daily for 28 days
- Inhalational anthrax (post-exposure): 500 mg daily for 60 days
- Plague: 500 mg daily for 10-14 days
Dosing Strategy and Rationale
The 750 mg high-dose, short-course (5-day) regimen is preferred when applicable because it maximizes concentration-dependent bactericidal activity, reduces resistance development, and improves compliance. 2, 3 This regimen achieves higher drug exposure designed to overcome the most common fluoroquinolone resistance mechanisms 2.
Standard Dosing in Normal Renal Function
- Administer once every 24 hours
- Can be given without regard to food 1
- Oral formulation is bioequivalent to IV, allowing seamless transition between routes 3, 4
Renal Dose Adjustments
Dose adjustment is mandatory when creatinine clearance falls below 50 mL/min 1:
- CrCl 20-49 mL/min: Reduce dose or extend interval based on initial dose
- CrCl 10-19 mL/min: Further reduction required
- Hemodialysis/ESRD: Use not recommended due to insufficient data 5
Clinical Context and Positioning
Respiratory Tract Infections
Levofloxacin is NOT first-line for CAP in previously healthy adults but IS recommended for patients with comorbidities or recent antibiotic exposure (within 3 months) who are at higher risk for resistant pathogens. 2 The guideline evidence emphasizes that while levofloxacin has enhanced activity against S. pneumoniae compared to ciprofloxacin, treatment failures have occurred with the 500 mg dose due to emerging resistance, which led to FDA approval of the higher 750 mg dose 2.
Urinary Tract Infections
Standard empiric therapy remains cephalosporins; levofloxacin should be reserved for pyelonephritis or complicated UTI when first-line agents are inappropriate due to resistance, allergy, or adverse event history 2.
Gastrointestinal Infections
Levofloxacin demonstrates efficacy for typhoid fever, invasive salmonellosis, and shigellosis, though caution is warranted for travelers returning from India due to fluoroquinolone-resistant Salmonella typhi strains 2.
Critical Contraindications and Warnings
Absolute Contraindications
- Myasthenia gravis: Risk of exacerbation 1
- History of tendon disorders related to fluoroquinolone use 1
- Known hypersensitivity to levofloxacin or other fluoroquinolones 1
Serious Warnings (Black Box)
- Tendinitis and tendon rupture: Can occur during or after therapy, risk increased in patients >60 years, on corticosteroids, or with kidney/heart/lung transplants 1
- Peripheral neuropathy: May be irreversible 1
- CNS effects: Seizures, increased intracranial pressure, toxic psychosis 1
- Exacerbation of myasthenia gravis: Can be fatal 1
Other Significant Adverse Effects
- QTc prolongation: Avoid in patients with known prolongation, uncorrected hypokalemia, or concurrent use of Class IA/III antiarrhythmics 1
- Hepatotoxicity: Monitor for signs of liver injury 1
- Clostridioides difficile colitis: Consider if diarrhea develops 1
- Blood glucose disturbances: Both hypo- and hyperglycemia reported 1
- Photosensitivity: Though lower risk than some fluoroquinolones 4
- Crystalluria: Maintain adequate hydration 1
Drug Interactions
Administer levofloxacin at least 2 hours before or 2 hours after antacids containing magnesium/aluminum, sucralfate, iron, multivitamins with zinc, or didanosine preparations 1. These chelating agents significantly reduce levofloxacin absorption.
Resistance Considerations
The critical caveat is that levofloxacin should be used judiciously to preserve its effectiveness against resistant pathogens. 6 Data suggest fluoroquinolones may drive class-wide resistance in Pseudomonas aeruginosa and select for resistance in S. pneumoniae 6. Current U.S. resistance rates for S. pneumoniae to levofloxacin remain <1%, but this requires ongoing stewardship 4.
Reserve levofloxacin for complicated infections, treatment failures with first-line agents, or documented resistant pathogens rather than routine community-acquired infections 6.